Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics, Multiplicom Bundle NGS Products for CDx

NEW YORK (GenomeWeb) – Sophia Genetics and Multiplicom have agreed to combine their respective products to provide next-generation sequencing-based solutions for solid tumor testing to hospitals and private laboratories in Germany and Austria.

Multiplicom develops, manufactures, and commercializes molecular diagnostic assays based on its Multiplex Amplification of Specific Targets for Resequencing (MASTR) technology, which are used for cancer testing, genetic disease predisposition, and congenital defects in pregnancy. Its portfolio includes the CE-IVD-marked BRCA MASTR Dx and Clarigo assays for breast and ovarian cancer predisposition and non-invasive prenatal testing respectively. Sophia Genetics, meanwhile, sells informatics tools for analyzing sequencing-based test results in clinical contexts. Its DDM analytics solution is a software-as-a-service platform for routine diagnostic testing that integrates modules for clinical next-generation sequencing data analysis.

Under the terms of the agreement, the companies will bundle Sophia's DDM with Multiplicom's molecular diagnostic kits, and Sophia will market the combined solution to prospective customers.

Financial details of the deal were not disclosed.

The benefits of the combined offering include improve turnaround time for sample processing and access to advanced genomic analytics tools, according to Sophia Founder and CEO Jurgi Camblong. "We can now offer hospitals and laboratories a streamlined solution for molecular diagnostics, and thereby accelerate the adoption of next-generation sequencing in routine clinical diagnostics," he said in a statement.

The partnership "further underpins our commitment to provide accurate information to physicians and patients that improves quality of life and treatment outcome," Multiplicom CEO Dirk Pollet added.

Earlier this year, Sophia Genetics partnered with Integrated DNA Technologies to provide customers with target capture and data analytics for next-generation sequencing-based clinical diagnostics. More recently, it announced a $1 million initiative supported by the Swiss Commission for Technology and Initiative, to develop encryption methods and standards to protect data transferred between patient registries in hospitals and on genomic platforms.